AzTrials
AzTrials

Esophageal CancerNCT03671642

Perioperative Perfusion Measurement - a Feasibility and Usability Study

A study testing Q-ICG, White light perfusion assessment and Fluorescence angiography in people with Esophageal Cancer, run by Copenhagen University Hospital, Rigshospitalet at 1 site in Denmark.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study will investigate a new method to assess tissue perfusion during surgery for esophageal cancer. When a tumor in the distal esophagus is removed, the ends of the esophagus and the stomach must be reconnected by an anastomosis. An optimal perfusion is essential to ensure a good healing of the anastomosis. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Esophageal Cancer
What is being tested?
Q-ICG, White light perfusion assessment and Fluorescence angiography
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
1 siteDenmark
Study dates
8 Aug 2018to 11 Mar 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients (above 18 years) scheduled for planned open or robot-assisted resection of the gastroesophageal junction (GI junction) for GI junctional cancer.

Who cannot join

  • Allergy towards; iodine, indocyanine green or shellfish
  • Liver insufficiency
  • Thyrotoxicosis
  • Pregnancy or lactation
  • Legally incompetent for any reason
  • Withdrawal of inclusion consent at any time

Trial locations and contacts

1 site in 1 country.

Denmark1 site
  • Department of Surgical Gastroenterology - Rigshospitalet

    Copenhagen Ø, 2100

Other trials in Denmark

About this study

This study will investigate a new method to assess tissue perfusion during surgery for esophageal cancer.

When a tumor in the distal esophagus is removed, the ends of the esophagus and the stomach must be reconnected by an anastomosis. An optimal perfusion is essential to ensure a good healing of the anastomosis. If anastomotic leakage occurs, it may prolong hospital stay, increase the risk of serious complications and death, delay start-up of chemotherapy and worsen the long-term survival prognosis.

During the operation the blood supply to the ends of the esophagus and stomach will be assessed in different ways; The traditional where the surgeon looks and feels on the tissue, and newer methods with an indocyanine green and cameras that illuminate the tissue with near-infrared light. The surgeon will assess whether these methods change the decision on where the ends should be sewn together.

Read the detailed description

Introduction:

An optimal perfusion is essential in gastrointestinal surgery when resection of a cancerous tissue requires an anastomosis, since impaired perfusion seems to be associated with increased risk of anastomotic leakage (AL). AL is a severe complication with the risk of; prolonged hospital stay, cancer recurrence, permanent stoma in colorectal surgery, and increased short and long-term mortality. To avoid poor perfusion of an anastomosis, perfusion assessment is necessary during the operative procedure. Traditionally, perfusion is assessed visually and manually by the surgeon by judging the; color of the tissue, bleeding from the resection line, and the arterial supply pulse by palpation. These methods have earlier been shown to be unreliable and prone to observer bias. Furthermore, palpation of arterial supply is not possible in laparoscopic or robot-assisted surgery, and the increased use of staplers to divide the bowel leaves no bleeding resection lines. Therefore newer methods for perfusion assessment have been investigated, and fluorescence angiography (FA) and laser speckle contrast imaging (LSCI) has shown very promising results. In a systematic review of nonrandomized studies, the leakage rate in 916 colorectal resections was significantly lower when using FA compared to controls (3.3%, [95% CI: 1.97-4.63%] vs 8.5%, [95% CI: 4.8-12.2%], p=0.0055).

In FA, the tissue of interest is exposed to near-infrared (NIR) light simultaneously with intravenous injection of a fluorescent dye. When the dye reaches the illuminated area, it fluoresces, and a camera with a special filter can visualize the microcirculation of the tissue on a monitor. Many NIR-camera systems are on the market, combining the technique with conventional laparoscopic or robotic equipment, and several non-randomized studies have indicated that FA may reduce the anastomotic leakage rate in gastrointestinal surgery. Most surgeons are using only a visual subjective assessment of the FA, which may be prone to observer bias. Moreover, if the camera is not held at a standard distance from the tissue, or a different concentration of dye is used, a false negative or positive assessment of the perfusion may be made. Therefore, it has been argued that there is a need for an objective unbiased quantitative assessment tool in FA.

A quantification algorithm that provides a fluorescence-time curve and a quantitative parameter of perfusion, the normalized slope has previously been published, where a nearly linear correlation to regional flow was found. Until now measurements has been performed as analyses of video-recordings after the procedure.

In order to use the method in a clinical setting, development and testing of a tool that may be operated by the surgeon during the procedure to perform perioperative measurements is of high importance. A touchscreen tablet has been developed, in order to perform live perioperative quantitative perfusion assessment using FA. The tool may be used with several systems including Karl Storz fluorescence laparoscopic equipment and the daVinci SI or XI from Intuitive. This tool is essential in order to implement the technology into daily practice, as it allows the surgeon to get an immediate quantitative parameter of perfusion (normalized slope) at desired regions of interest. The interface of the tool should be easy to use and provide fluorescence-time curves to control the automated calculation of the normalized slope. In addition, a color-coded map of perfusion intensity should be provided as an overlay on the white light picture of the bowel investigated.

Aim:

The touchscreen tablet has currently only been tested in animal surgery. The aim of the present study is to investigate if the use of a perioperative quantitative perfusion assessment tool may improve the perfusion assessment during surgery in humans.

Hypotheses:

  • Perioperative perfusion assessment with FA will change the point of resection determined by conventional visual perfusion assessment in GI junctional procedures.
  • Quantitative perfusion assessment with FA (Q-ICG) will further change the point of resection determined by visual assessment of the FA and conventional visual assessment of perfusion in GI junctional procedures.

Primary endpoints:

  • Feasibility of perfusion assessment with traditional visual, visual FA, and Q-ICG - complied by completion rates.
  • The feasibility and usability of the tool, the surgeons' experiences with the Q-ICG-tablet interface - rated on a validated questionnaire, the System Usability Scale.

Secondary endpoints:

  • Differences in the distance from the determined resection points using traditional assessment, FA, and Q-ICG.

Methods

Study Design:

The study will be conducted as an observational feasibility and usability trial in patients undergoing open or robot-assisted resection of the gastroesophageal junction (GI junction) in a single university hospital center (Rigshospitalet, Department of Surgical Gastroenterology). Patients will serve as their own control. Demographic information (tumor-staging, gender, age, BMI, neoadjuvant treatment, ASA-classification, smoking, alcohol, medication etc.) will be collected from the electronic patient records. In addition, postoperative events, especially the presence of an anastomotic leakage, will be noted 30 days postoperatively. No formal sample size calculation has been performed as the study is a feasibility study. 20 patients will be included. Participating patients will receive the same standard post- and peri-operative care and follow-up as patients not included in the study.

Indocyanine green Indocyanine green (ICG) is a well-described nontoxic tricarbocyanine dye used for decades in ophthalmology, cardiology, and hepatology. Very few mild adverse reactions have been reported, but caution in patients with thyrotoxicosis, allergy towards iodine or indocyanine green should be made. When injected intravenously it binds to blood lipoproteins and is solely metabolized by the liver and excreted in the bile, with a short half-life of approximately 4-5 minutes.

Surgical procedure and perfusion assessment When the dissection and division of the feeding blood vessels are complete and the gastric conduit established and drawn to the thorax, the gastrointestinal surgeon will choose the most proximal point possible on the conduit for the anastomosis (Anastomotic point surgeon, APS) by pointing while a picture is captured, blinded for the thoracic surgeon. A sterile paper ruler will be introduced to the thorax, in order to measure the distance between the chosen resection points. Then, LSCI measurement of the conduit is performed, and finally, a bolus of ICG (0.25 mg/kg body weight) will be injected intravenously and flushed with 5 mL of saline, and the tissue of interest exposed to NIR-light (excitation wavelength 750-800 nm) and emission observed at 800 nm (FA). During the video-captures of LSCI and ICG-FA, the respiration will be paused for a maximum of 20 seconds initiated at the moment of saline injection. After the FA the thoracic surgeon will by visual assessment determine and mark a new anastomotic point by pointing at the most proximal point possible on the conduit for the anastomosis, while a picture is taken (anastomotic point fluorescence angiography, APFA). After the quantitative FA the surgeon will again mark an anastomotic point (APQFA). The final anastomotic point will be chosen by the primary gastrointestinal and the thoracic surgeon, and if the assessment of FA or quantitative FA will influence this decision is solely up to the surgeon. The same points will be marked on the LSCI picture but not revealed to the surgeon since the quantitative assessment of the LSCI demands on post hoc data-analysis.

When the surgeon decides how much tissue to resect to ensure an optimal anastomotic perfusion, care must be taken not to cause tension to the anastomosis by resecting too much of the gastric conduit or the esophagus, as tension is a known risk factor of anastomotic leakage. Again, the level of resection is solely decided by the surgeon and this decision should, as always, be made by balancing factors of tension, perfusion, and excessive tissue loss - all combined to ensure an optimal anastomotic healing.

Laparoscopic fluorescence angiography A laparoscope (ICG-Hopkins telescope 30°, 10 mm, Karl Storz Gmbh and Co. KG, Tüttlingen, Germany) will be connected to a camera system (IMAGE1, Karl Storz Gmbh and Co. KG, Tüttlingen, Germany) and a light-source (D-light P, Karl Storz Gmbh and Co. KG, Tüttlingen, Germany) will supply the excitatory light and record the FA. The laparoscope will be fixed in a mechanical holding arm 10 cm from the tissue of interest, ensuring a stable position throughout the experiment.

Robot-assisted fluorescence angiography A surgical robot DaVinci SI (Intuitive Surgical Inc., Sunnyvale, CA, USA) and the Firefly Fluorescence Imaging system will be used. The camera will be fixed 10 cm from the tissue of interest, ensuring a stable position throughout the experiment.

Quantitative fluorescence angiography (Q-ICG) A video capture device (Av.io HD™, Epiphan video, California, USA) will be connected to the surgical robot or the laparoscopic camera system and transfer the video capture to a tablet (Microsoft Surface Pro4 I5, Microsoft, Redmond, WA, USA). A program developed to quantify the FA will be installed. Here the operator can choose regions of interest to quantify from the captured video sequence. A color grading of perfusion will be provided as well as quantitative values from specific points. From this assessment, the surgeon will again determine a new resection point (APQFA).

Comparison of resection points The distance from the tumor to the RPS will be measured before the FA using the paper ruler. In addition, the distance from the APS to APFA and APQFA will be measured using the ruler, either during the procedure or post hoc using the video-capture. The comparison of the distance will be made on the distance of each point from the tumor.

Feasibility The feasibility will be investigated by comparison of completion rates of the different perfusion assessment methods; traditional, FA, Q-ICG.

Usability The usability of the quantitative perfusion assessment tool will be investigated with a validated questionnaire, the System Usability Scale, answered by the surgeon immediately after the procedure.

Statistics Comparison of data will be performed using Mann Whitney U test or a paired sample t-test depending on distribution normality. P-values < 0.05 is considered significant. No formal sample size calculation has been made, as the study is considered a feasibility trial. 20 patients will be recruited. Statistic evaluation was performed using IBM SPSS Statistics © (v 22.0 SPSS Inc. Chicago, IL, USA).

Adverse events, risks, and disadvantages Adverse events associated with the use of ICG are extremely rare and severe anaphylactic reactions are almost never occurring. However, safety precautions have been made by excluding patients with allergy to iodine, ICG or shellfish. In addition, no patients with liver insufficiency, thyrotoxicosis, ongoing pregnancy, or lactating women will be included.

Being tested
Q-ICG, White light perfusion assessment, Fluorescence angiography
Keywords
perfusion, indocyanine green angiography, feasibility study
Medical subject headings
Esophageal Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Q-ICGDevice

    Quantitative perfusion assessment with indocyanine green on a touch screen tablet

  • White light perfusion assessmentProcedure or surgery

    Traditional visual perfusion assessment in white light

  • Fluorescence angiographyProcedure or surgery

    Perfusion assessment with fluorescence angiography - without quantification

Study groups in NCT03671642
Study groupRoleWhat they receive
Perfusion assessmentExperimentalQ-ICG: quantitative perfusion assessment with FA White light perfusion assessment FA: fluorescence angiography without quantification
Receives: Device: Q-ICG; Procedure: White light perfusion assessment; Procedure: Fluorescence angiography

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Completion rates

    Feasibility of perfusion assessment with traditional visual, visual FA, and Q-ICG

    Measured: during surgery

Secondary outcomes (2)
  1. Differences in resection points

    Differences in the distance from the determined resection points using traditional assessment, LSCI, FA, and quantitative FA.

    Measured: up to 6 months

  2. System Usability Scale

    The feasibility and usability of the tool, the surgeons' experiences with the Q-ICG tablet interface - rated on a validated questionnaire, the System Usability Scale - https://www.usability.gov/how-to-and-tools/methods/system-usability-scale.html.

    Scores ranges from 0-100, where a score of 68 is considered average.

    Measured: up to one week

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Sep 2018
  2. Study start8 Aug 2018
  3. Primary completion11 Mar 2019
  4. Study completion11 Mar 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
10 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03671642
Sponsor's protocol ID
H-18006334
Status last verified
Mar 2019
First submitted
8 Aug 2018
Last updated
12 Mar 2019
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Nerup N, Andersen HS, Ambrus R, Strandby RB, Svendsen MBS, Madsen MH, Svendsen LB, Achiam MP. Quantification of fluorescence angiography in a porcine model. Langenbecks Arch Surg. 2017 Jun;402(4):655-662. doi: 10.1007/s00423-016-1531-z. Epub 2016 Nov 15.

    PubMed 27848028

Questions about this trial

What is this clinical trial studying?

A study testing Q-ICG, White light perfusion assessment and Fluorescence angiography in people with Esophageal Cancer, run by Copenhagen University Hospital, Rigshospitalet at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Completion rates (time frame: during surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03671642, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2019; AzTrials last refreshed its copy on 2 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in